Anzeige
Mehr »
Freitag, 01.08.2025 - Börsentäglich über 12.000 News
Der KI-Energiekollaps: Uran auf kritischem Kurs - und Foremost Clean Energy entflammt den Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H65A | ISIN: NL0010391025 | Ticker-Symbol: PHGN
Tradegate
31.07.25 | 20:32
0,960 Euro
+11,63 % +0,100
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMING GROUP NV Chart 1 Jahr
5-Tage-Chart
PHARMING GROUP NV 5-Tage-Chart
RealtimeGeldBriefZeit
0,9510,96031.07.
0,9500,96031.07.

Aktuelle News zur PHARMING Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoPharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M3
DoPharming Group N.V. - 6-K, Report of foreign issuer1
DoPharming reports Q2 results-
DoPharming Group N.V.: Pharming Group reports second quarter and first half 2025 financial results and provides business update251Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased...
► Artikel lesen
17.07.Pharming Group N.V.: Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31317Leiden, the Netherlands, July 17, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second...
► Artikel lesen
PHARMING Aktie jetzt für 0€ handeln
24.06.Pharming Group N.V. - 6-K, Report of foreign issuer7
24.06.Pharming Group N.V.: Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis8
11.06.Pharming Group N.V. - 6-K, Report of foreign issuer11
11.06.Pharming Group N.V.: Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders400Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM)...
► Artikel lesen
28.05.Pharming Group N.V.: Pharming Group to participate in June investor conferences431Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences...
► Artikel lesen
09.05.Pharming GAAP EPS of -$0.02 beats by $0.01, revenue of $79.09M beats by $15.15M3
08.05.Pharming Group N.V. - 6-K, Report of foreign issuer3
08.05.Pharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business update591First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting...
► Artikel lesen
30.04.Pharming Group N.V.: Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director5
30.04.Pharming Group N.V. - 6-K, Report of foreign issuer5
25.04.Pharming Group N.V.: Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)6
24.04.H.C. Wainwright maintains Buy rating on Pharming Group stock15
24.04.NICE issues final guidance endorsing Pharming's APDS therapy3
24.04.Pharming Group N.V.: Pharming Group to report first quarter 2025 financial results on May 8466Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results...
► Artikel lesen
23.04.Pharming Group N.V. - 6-K, Report of foreign issuer1
Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1